By Deena Beasley (Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered ...

Annual Meeting, held 30 May-3 June 2025, primary results were presented from the ASCENT-04/KEYNOTE-D19 study investigating ...

GILD posts strong phase III results for Trodelvy plus Keytruda, cutting TNBC progression risk by 35% compared with standard ...

After meeting the mark alongside Keytruda in PD-L1-positive breast cancer earlier this year, Gilead Sciences' antibody-drug ...

Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

The use of Gilead’s Trodelvy and Merck’s Keytruda together could be practice-changing based on the results of a new study ...

Gilead Sciences (NASDAQ:GILD) announced Saturday that its antibody-drug conjugate Trodelvy, in combination with Merck’s (NYSE ...

In the control arm, 43% of patients crossed over to receive Trodelvy monotherapy after disease progression, representing 81% of those who received any subsequent treatment following chemo-Keytruda, ...

Gilead is conducting several other Trodelvy studies, including a trial of the drug as an initial treatment for triple-negative breast cancer patients who do not express PD-L1.

Gilead Sciences, Inc. GILD announced positive data on breast cancer drug Trodelvy (sacituzumab govitecan-hziy) from the late-stage ASCENT-04/KEYNOTE-D19 study. Data from the phase III ASCENT-04 ...